BillionToOne Inc Ordinary Shares - Class A BLLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
-
BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
-
/C O R R E C T I O N — BillionToOne/
-
BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar
Trading Information
- Previous Close Price
- $106.44
- Day Range
- $103.51–108.58
- 52-Week Range
- $61.96–150.44
- Bid/Ask
- $101.11 / $108.62
- Shares Outstanding
- 47.19M
- Market Cap
- $4.99B
- Volume/Avg
- 586,947 / 696,263
Key Statistics
- Price/Earnings (Normalized)
- 111.79
- Price/Sales
- 5.65
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 713
- Website
- https://www.billiontoone.com
Valuation
|
Metric
|
BLLN
|
|---|---|
Price/Earnings (Normalized) | 111.79 |
Price/Book Value | 9.22 |
Price/Sales | 5.65 |
Price/Cash Flow | 24.88 |
Price/Earnings
BLLN
Financial Strength
|
Metric
|
BLLN
|
|---|---|
Quick Ratio | 11.19 |
Current Ratio | 11.69 |
Interest Coverage | 580.85 |
Quick Ratio
BLLN
Profitability
|
Metric
|
BLLN
|
|---|---|
Return on Assets (Normalized) | 15.39% |
Return on Equity (Normalized) | 40.27% |
Return on Invested Capital (Normalized) | 21.03% |
Return on Assets
BLLN
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|@x&!@G# | LOCK|@> | $241B | |||
| Danaher Corp
DHR
| LOCK|<vs<Dt& | LOCK|JyY | $149B | |||
| Agilent Technologies Inc
A
| LOCK|H?q$#hG^ | LOCK|<zX | $47B | |||
| IQVIA Holdings Inc
IQV
| LOCK|$L?K$M | LOCK|g@x# | $43B | |||
| Waters Corp
WAT
| LOCK|w@hj?QN | LOCK|Jyz | $42B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|XHFt?l? | LOCK|lhq | $41B | |||
| Illumina Inc
ILMN
| LOCK|NY>gJrB | LOCK|x&<f | $40B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|Km?Lb&>N | LOCK|?D^j$ | $30B | |||
| Quest Diagnostics Inc
DGX
| LOCK|KggwRs | LOCK|@<nK | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|nk<qjh! | LOCK|<&Z> | $25B |
United States